Scientific capability / Isoform-Specific Target Assessment

Which version of the target should the intervention affect?

A gene name can conceal protein products with different structures or functions. BioTwin’s isoform assessment asks whether that distinction changes what to inhibit, preserve or measure.

Current work Evidence-guided target assessment

Move from the gene label to the therapeutic job

Resources such as Ensembl already represent transcripts, exons and translated protein sequences. BioTwin’s curated assessment uses isoform context to challenge an intervention hypothesis: are the relevant products interchangeable, or could suppressing one have a different consequence from suppressing another?

Put the distinction into the assay

Compare the relevant sequence, expression and functional annotations, then identify the assay that can separate the products in the intended setting. A gene-level readout may be adequate for one question and conceal the distinction that matters for another.

A targeted assessment, with coverage stated

Current work supports curated isoform comparisons. It does not establish exhaustive isoform coverage or measured isoform selectivity. Expression and function in the target tissue are evidence to obtain, rather than properties to infer from a transcript label.

Carry the right protein product into the next calculation

An interface or modification-state analysis could change when its input sequence changes. An RNA-directed strategy raises a related question about transcript specificity. Each requires its own compatible inputs and functional evidence.

Further reading

Make the target name precise enough for the decision.

Identify the isoforms, intended tissue and functional distinction that could change the assay or intervention.